Vertex Pharmaceuticals Incorporated (LON:0QZU)
469.86
-10.45 (-2.18%)
At close: Jul 11, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B USD in the quarter ending March 31, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to $11.10B, up 8.98% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.10B
Revenue Growth
+8.98%
P/S Ratio
10.36
Revenue / Employee
$1.82M
Employees
6,100
Market Cap
89.00B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Vertex Pharmaceuticals News
- 5 days ago - Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
- 7 days ago - Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch - Seeking Alpha
- 8 days ago - Vertex to Announce Second Quarter 2025 Financial Results on August 4th - Business Wire
- 8 days ago - Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others - CNBC
- 15 days ago - Vertex's next-generation cystic fibrosis drug gets EU approval - Reuters
- 15 days ago - Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
- 16 days ago - $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
- 20 days ago - Vertex Pharmaceuticals Unusual Options Activity - Benzinga